Zydus files IND application for ZYT1 a novel candidate to treat dyslipidemia

Zydus files IND application for ‘ZYT1’ a novel candidate to treat dyslipidemia Ahmedabad, October 16, 2008 Zydus Cadila, a global healthcare provider and one of India’s leading healthcare companies, announced the filing o f the IND application for ZYT1 - a novel lipid lowering molecule with the DCGI. Designed and developed at the Zydus Research Centre, ZYT1 is a novel, anti - dyslipidemic agent which may provide an alternative to statins or be an add - on to statin therapy. I n preclinical studies, ZYT1 has demonstrated beneficial effect on LDL - cholesterol and triglycerides, comparable to the effects seen with statins. When combined with statins, ZYT1 exhibited a pronounced effect in lowering LDL - cholesterol and triglycerides w ith the added benefit of a very high margin of safety. Dyslipidemia is a clinical condition characterized by an elevation of cholesterol and/or triglycerides in the bloodstream. Over 80% of patients with coronary heart disease, even those currently on med ication, remain above the targeted levels for cholesterol. Speaking on the new development, Mr. Pankaj Patel, Chairman and Managing Director, Zydus Cadila, said, “There is currently a huge unmet need for new therapies in treating dyslipidemia patients. I n ZYT1, we see an interesting possibility that can adequately bridge this gap and usher in significant improvement in meeting treatment goals.” Heart disease accounts for approximately 17 million deaths annually. Cardiovascular segment is the largest ther apeutic segment in the world pharmaceutical market and treatment of dyslipidemia represents a major sector of this market, which is expected to grow from $36 billion in 2007 to $42 billion in 2012. Zydus Cadila now has six candidates in various stages of clinical development, with two candidates in advanced Phase II clinical development. The Zydus Research Centre has over 15 programmes in the pre - clinical development stage and is focused on metabolic, cardiovascular and inflammation therapeutic areas. Wit h over 375 research professionals spearheading its NME research programme, Zydus has in - house capabilities to conduct discovery research from concept to IND enabling pre - clinical development and human proof - of - concept clinical trials. ###

The release as fetched from its publisher. zyduslife.com ↗